Know Cancer

forgot password

Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations

Phase 2
18 Years
85 Years
Open (Enrolling)
Acute Myeloid Leukemia

Thank you

Trial Information

Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations

Current enrollment is open only to FLT3-ITD positive, Cohort 1.

Inclusion Criteria:

1. Males and females age ≥18 years in second relapse or refractory.

2. Males and females age ≥60 years in first relapse or refractory.

3. Must have baseline bone marrow sample taken.

4. Morphologically documented primary AML or AML secondary to myelodysplastic syndrome
(MDS with ≥20% bone marrow or peripheral blasts), as defined by the World Health
Organization (WHO) criteria, confirmed by pathology review at treating institution.

5. Able to swallow the liquid study drug.

6. ECOG performance status of 0 to 2

7. In the absence of rapidly progressing disease, the interval from prior treatment to
time of AC220 administration will be at least 2 weeks for cytotoxic agents or at
least 5 half-lives for noncytotoxic agents. The use of chemotherapeutic or
antileukemic agents other than hydroxyurea is not permitted during the study with the
possible exception of intrathecal (IT) therapy at the discretion of the Investigator
and with the agreement of the Sponsor.

8. Persistent chronic clinically significant non-hematological toxicities from prior
treatment must be ≤Grade 1.

9. Prior therapy with FLT3 inhibitors is permitted, except previous treatment with

10. Serum creatinine ≤1.5 × ULN and glomerular filtration rate (GFR) > 30 mL/min

11. Serum potassium, magnesium, and calcium levels should be at least within
institutional normal limits.

12. Total serum bilirubin ≤1.5 × ULN

13. Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤2.5 × ULN

14. Females of childbearing potential must have a negative pregnancy test (urine β-hCG).

15. Females of childbearing potential and sexually mature males must agree to use a
medically accepted method of contraception throughout the study.

16. Written informed consent must be provided.

Exclusion Criteria:

1. Patients over the age of 85 years except at the discretion of the Investigator and
with agreement of the Sponsor.

2. Diagnosis of acute promyelocytic leukemia

3. Diagnosis of chronic myelogenous leukemia (CML) in blast crisis

4. AML in relapse or refractory after 3 or more previous lines of chemotherapy (and/or
HSCT) treatment

5. AML or antecedent MDS secondary to prior chemotherapy

6. Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI
CTCAE v4 from prior chemotherapy

7. Patients who have had HSCT and are within 100 days of transplant and/or are still
taking immunosuppressive drugs and/or have clinically significant graft-versus-host
disease requiring treatment and/or have >Grade 1 persistent non hematological
toxicity related to the transplant

8. Clinically active central nervous system (CNS) leukemia. Patients with CNS leukemia,
which is controlled, but who are still receiving IT therapy at study entry may be
considered eligible and continue receive IT therapy at the discretion of the
Investigator and with agreement of the Sponsor.

9. Patients who have previously received AC220

10. Disseminated intravascular coagulation (DIC) (diagnosis by laboratory or clinical

11. Major surgery within 4 weeks prior to enrollment in the study

12. Radiation therapy within 4 weeks prior to, or concurrent with study

13. Use of concomitant drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors
are prohibited with the exception of antibiotics, antifungals, and other
antimicrobials that are used as standard of care to prevent or treat infections and
other such drugs that are considered absolutely essential for the care of the

14. Uncontrolled or significant cardiovascular disease

15. Women who are pregnant, lactating, or unwilling to use contraception if of
childbearing potential

16. Men who are unwilling to use contraception if their partners are of childbearing

17. Active, uncontrolled infection

18. Human immunodeficiency virus positivity

19. Active hepatitis B or C or other active liver disease

20. History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the
possible exception of patients in complete remission

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Composite complete remission rate (CRc), defined as the confirmed rate of complete remission (CR) plus complete remission with incomplete platelet (CRp) or incomplete hematological recovery (CRi).

Outcome Time Frame:

Interim analysis following recruitment of 60 patients. Final analysis following study completion.

Safety Issue:


Principal Investigator

Guy Gammon, MB BS, MRCP

Investigator Role:

Study Director

Investigator Affiliation:

Interim Chief Medical Officer, Ambit Biosciences Corporation


United States: Food and Drug Administration

Study ID:




Start Date:

November 2009

Completion Date:

December 2013

Related Keywords:

  • Acute Myeloid Leukemia
  • AML
  • AC220
  • acute
  • FLT3
  • inhibitor
  • kinase
  • leukemia
  • leukaemia
  • myeloid
  • relapsed
  • refractory
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid



Roswell Park Cancer Institute Buffalo, New York  14263
Mayo Clinic Rochester, Minnesota  55905
University of Iowa Hospitals and Clinics Iowa City, Iowa  52242
Milton S. Hershey Medical Center Hershey, Pennsylvania  17033
Northwestern Memorial Hospital Chicago, Illinois  60611
Rush University Medical Center Chicago, Illinois  60612-3824
University of Wisconsin Hospital and Clinics Madison, Wisconsin  53792-0001
Seattle Cancer Care Alliance Seattle, Washington  98109
Columbia University New York, New York  10032-3784
University of California, San Francisco San Francisco, California  94143
University of Michigan Medical Center Ann Arbor, Michigan  48104-0914
M.D. Anderson Cancer Center Houston, Texas  77030
University of Maryland Baltimore, Maryland  21201
Oregon Health and Science University Portland, Oregon  97201
Indiana University Indianapolis, Indiana  46202
Karmanos Cancer Institute Detroit, Michigan  48201
Johns Hopkins Hospital Baltimore, Maryland  21287
Abramson Cancer Center Philadelphia, Pennsylvania  19104
The Vanderbuilt Clinic Nashville, Tennessee  37232
Clinical Trials Center Nashville, Tennessee  37212